Carboplatin treatment of antiestrogen-resistant breast cancer cells

Larsen,Mathilde  S.; Yde,Christina  W.; Christensen,Ib  J.; Lykkesfeldt,Anne  E.

doi:10.3892/ijo.2012.1623

Carboplatin treatment of antiestrogen-resistant breast cancer cells

Authors:
- Mathilde S. Larsen
- Christina W. Yde
- Ib J. Christensen
- Anne E. Lykkesfeldt
View Affiliations

Affiliations: Breast Cancer Group, Unit of Cell Death and Metabolism, Danish Cancer Society Research Center, DK-2100 Copenhagen Ø, Denmark, Finsen Laboratory, Rigshospitalet, DK-2200 Copenhagen, Denmark
Published online on: September 6, 2012 https://doi.org/10.3892/ijo.2012.1623
Pages: 1863-1870

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Antiestrogen resistance is a major clinical problem in current breast cancer treatment. Therefore, biomarkers and new treatment options for antiestrogen-resistant breast cancer are needed. In this study, we investigated whether antiestrogen‑resistant breast cancer cell lines have increased sensitivity to carboplatin, as it was previously shown with cisplatin, and whether low Bcl-2 expression levels have a potential value as marker for increased carboplatin sensitivity. Breast cancer cells resistant to the pure antiestrogen fulvestrant, and two out of four cell lines resistant to the antiestrogen tamoxifen, were more sensitive to carboplatin treatment compared to the parental MCF-7 cell line. This indicates that carboplatin may be an advantageous treatment in antiestrogen‑resistant breast cancer; however, a marker for increased sensitivity would be needed. Low Bcl-2 expression was correlated with increased carboplatin response in the tamoxifen‑resistant cell line MCF-7/TAMR-1 and overexpression of Bcl-2 in this cell line resulted in significantly reduced carboplatin sensitivity, confirming the anti-apoptotic role of Bcl-2. However, neither Bcl-2 expression alone, nor Bcl-2 in combination with Bcl-xL and Bax, could explain the observed responses to carboplatin in all tamoxifen‑resistant cell lines, indicating that more markers are needed to predict the response to carboplatin in tamoxifen‑resistant breast cancer.

View Figures

View References

1.	Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2:101–112. 2002. View Article : Google Scholar : PubMed/NCBI
2.	Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA and Walton P: Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer. 74:300–308. 1996. View Article : Google Scholar : PubMed/NCBI
3.	Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 17:409–422. 1999.PubMed/NCBI
4.	Perez EA: Carboplatin in combination therapy for metastatic breast cancer. Oncologist. 9:518–527. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Carrick S, Ghersi D, Wilcken N and Simes J: Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 3:CD0033742004.
6.	Martin M: Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer. 2:190–208. 2001. View Article : Google Scholar : PubMed/NCBI
7.	Decatris MP, Sundar S and O’Byrne KJ: Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev. 30:53–81. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Colbern GT, Hiller AJ, Musterer RS, Working PK and Henderson IC: Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model. J Inorg Biochem. 77:117–120. 1999. View Article : Google Scholar : PubMed/NCBI
9.	Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F and Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemo-therapeutic agents used for treatment of human breast cancers. Oncogene. 18:2241–2251. 1999. View Article : Google Scholar : PubMed/NCBI
10.	Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA and Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overex-pressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 16:2659–2671. 1998.
11.	Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A and Crown J; Breast Cancer International Research Group: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365:1273–1283. 2011. View Article : Google Scholar : PubMed/NCBI
12.	Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG and Stenvang J: Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther. 6:1869–1876. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
14.	Schorr K, Li M, Krajewski S, Reed JC and Furth PA: Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia. 4:153–164. 1999. View Article : Google Scholar : PubMed/NCBI
15.	Yde CW and Issinger OG: Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int J Oncol. 29:1397–1404. 2006.PubMed/NCBI
16.	Christensen GL, Jepsen JS, Fog CK, Christensen IJ and Lykkesfeldt AE: Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment. Breast Cancer Res Treat. 85:53–63. 2004. View Article : Google Scholar
17.	Larsen SS, Heiberg I and Lykkesfeldt AE: Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br J Cancer. 84:686–690. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Lykkesfeldt AE, Madsen MW and Briand P: Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 54:1587–1595. 1994.PubMed/NCBI
19.	Lykkesfeldt AE, Larsen SS and Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer. 61:529–534. 1995. View Article : Google Scholar : PubMed/NCBI
20.	Madsen MW, Reiter BE, Larsen SS, Briand P and Lykkesfeldt AE: Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res. 57:585–589. 1997.PubMed/NCBI
21.	Sekine I, Shimizu C, Nishio K, Saijo N and Tamura T: A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol. 14:112–119. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Lykkesfeldt AE and Sorensen EK: Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol. 31:131–138. 1992. View Article : Google Scholar : PubMed/NCBI
23.	Lykkesfeldt AE and Briand P: Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer. 53:29–35. 1986. View Article : Google Scholar : PubMed/NCBI
24.	Lundholt BK, Briand P and Lykkesfeldt AE: Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat. 67:199–214. 2001. View Article : Google Scholar
25.	Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ II, de Cremoux P, Stenvang P and Lykkesfeldt AE: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. 114:263–275. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S and Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55:4471–4478. 1995.
27.	Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P and Dogliotti L: p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res. 6:2751–2758. 2000.PubMed/NCBI
28.	Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
29.	Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 86:499–504. 1994. View Article : Google Scholar : PubMed/NCBI
30.	Benbrook DM and Masamha CP: The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Curr Cancer Drug Targets. 11:586–599. 2011. View Article : Google Scholar : PubMed/NCBI
31.	Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL and Lykkesfeldt AE: Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer. 12:599–614. 2005. View Article : Google Scholar : PubMed/NCBI